On the Metabolism and Pharmacokinetics of Prostaglandin E1 Administered by Intra-arterial or Intravenous Infusions
Both intra-arterial and intravenous infusions of prostaglandin (PG)E1 have been used in the treatment of peripheral arterial occlusive disease . However, only few data on the pharmacokinetics and metabolic fate of PGE1 in man are available so far [4, 6, 7, 10, 16]. We have recently described  plasma levels of PGE1 and its circulating metabolite 15-keto-13,14-dihydro-PGE1 (KH2PGE1) in the cubital vein of healthy volunteers receiving PGE1 infusions into the contralateral cubital vein. We have now compared plasma levels of PGE1 and KH2PGE1 in healthy volunteers treated with either intra-arterial or intravenous infusions of PGE1. Furthermore, since the initial metabolites of PGE1 15-keto-PGE1 and KH2PGE1 have only negligible biological activity [1, 18], we have additionally determined the occurrence of 13,14-dihydro-PGE1 (H2PGE1), a biologically active metabolite [1, 3, 18], during intravenous PGE1 infusions in patients with peripheral arterial occlusive disease .
KeywordsIntravenous Infusion Adult Respiratory Distress Syndrome Arterial Occlusive Disease Peripheral Arterial Occlusive Disease Cubital Vein
Unable to display preview. Download preview PDF.
- 3.Braun M, Ney P, Szymanski Ch, Bruch L, Schrbr K (1991) 13,14-dihydro-PGE1, a potent inhibitor of human platelet and neutrophil activation. Br J Pharmacol 102: 90 PGoogle Scholar
- 12.Peskar BA, Hesse WH, Rogatti W, Diehm C, Rudofsky G, Schweer H, Seyberth HW (1991) Formation of 13,14-dihydro-prostaglandin Ex during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease. Pro-staglandins 41: 225–228Google Scholar
- 13.Peskar BA, Cawello W, Rogatti W, Rudofsky G. On the metabolism of prostaglandin E1 administered intravenously to human volunteers. J Physiol Pharmacol (in press)Google Scholar
- 16.Simmet T, Peskar BA, Wolf HRD (1986) On the metabolism of prostaglandin Ex in patients suffering from arterial occlusive disease. In: Sinzinger H, Rogatti W (eds) Prostaglandin E1 in atherosclerosis. Springer, Berlin Heidelberg New York, pp 8–12Google Scholar
- 17.Sinzinger H, Virgolini I, O’Grady J (1989) Clinical trials of PGE1, PGI2 and mimetics in patients with peripheral vascular disease. In: Schrör K, Sinzinger H (eds) Prostaglandins in clinical research. Liss, New York, pp 85–96Google Scholar
- 18.Westwick J (1976) The effect of pulmonary metabolites of prostaglandins E1, E2 and F2α on ADP-induced aggregation of human and rabbit platelets. Br J Pharmacol 58: 297 PGoogle Scholar